<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>Unscheduled bleeding on HRT — DGRefHelp Drafts</title>
  <link rel="stylesheet" href="../assets/site.css" />
</head>
<body>
  <div class="container">
    <div class="header">
      <div class="brand">
        <h1><a href="../index.html">DGRefHelp drafts</a> / Unscheduled bleeding on HRT</h1>
        <div class="sub">Primary care assessment + when to reassure/adjust vs urgent investigation. Anchored to BMS 2024 guideline. Includes referral-letter triage metrics.</div>
      </div>
      <div class="badges">
        <div class="badge">Mode: quick</div>
        <div class="badge">Last updated: 2026‑02‑09</div>
      </div>
    </div>

    <div class="grid">
      <div class="card">
        <div class="card-hd">
          <div class="tabs" data-tabs>
            <button class="tab" role="tab" data-tab="evidence" aria-selected="true">Evidence</button>
            <button class="tab" role="tab" data-tab="draft" aria-selected="false">DGRefHelp draft</button>
            <button class="tab" role="tab" data-tab="refs" aria-selected="false">References</button>
          </div>
          <div class="copybar">
            <button class="btn" data-copy-target="#draftText">Copy draft</button>
            <button class="btn" data-copy-target="#evidenceText">Copy evidence</button>
          </div>
        </div>

        <div class="card-bd">
          <div class="panel active" role="tabpanel" data-panel="evidence">
            <div id="evidenceText" class="section">
              <h3>Evidence summary (triangulated)</h3>

              <div class="callout ok">
                <strong>BMS 2024 “headlines” that change GP actions</strong>
                <ul>
                  <li><strong>Initial assessment</strong> should document bleeding pattern + exact HRT regimen + cancer risk factors, and include exam (abdo/pelvic) and relevant investigations (e.g., cervical screening if due/eligible, swabs if indicated, BMI).</li>
                  <li><strong>Risk factors (endometrial cancer)</strong>: major includes BMI ≥40 and Lynch/Cowden; minor includes BMI 30–39, diabetes, PCOS.</li>
                  <li><strong>Progestogen adequacy matters</strong>: ensure monthly progestogen dose is proportionate to oestrogen dose; minimum progestogen days per month for sequential regimens (NET/MPA 10 days; micronised progesterone 12 days).</li>
                  <li><strong>When to investigate</strong> (low-risk): if bleeding is within 6 months of starting HRT or persists within 3 months of a dose/prep change, BMS supports adjusting HRT/progestogen for a total of up to 6 months before escalating (if no cancer risk factors and bleeding not heavy/prolonged/daily).</li>
                  <li><strong>TVUS thresholds</strong> (if uniform and fully visualised): ≤4 mm for continuous combined HRT; ≤7 mm for sequential HRT → low cancer risk; adjust HRT and review. Above these thresholds → urgent endometrial assessment pathway.</li>
                </ul>
              </div>

              <div class="callout warn">
                <strong>Why this matters for local services</strong>
                <ul>
                  <li>BMS notes referral pressure increases when low-risk women are referred without attempting regimen optimisation; a clear DGRefHelp page can reduce unwarranted variation.</li>
                  <li>DGRefHelp should specify <strong>what to include in the referral</strong> so gynae can triage (regimen details, progestogen exposure, BMI/risk factors, bleeding pattern, TVUS details if done).</li>
                </ul>
              </div>
            </div>
          </div>

          <div class="panel" role="tabpanel" data-panel="draft">

            <div class="callout" style="margin-bottom:12px">
              <strong>Copy/paste HTML for Right Decisions accordion sections</strong>
              <div class="small">These snippets contain section content only (no internal headings). Paste each into the matching accordion section.</div>
              <div style="height:10px"></div>
              <div class="copybar" style="justify-content:flex-start">
                <button class="btn" data-copy-target="#htmlBackground">Copy Background HTML</button>
                <button class="btn" data-copy-target="#htmlAssessment">Copy Assessment HTML</button>
                <button class="btn" data-copy-target="#htmlPCM">Copy Primary care mgmt HTML</button>
                <button class="btn" data-copy-target="#htmlRefer">Copy Who to refer HTML</button>
                <button class="btn" data-copy-target="#htmlNotRefer">Copy Who not to refer HTML</button>
                <button class="btn" data-copy-target="#htmlRefs">Copy References HTML</button>
              </div>

              <details style="margin-top:10px">
                <summary class="small" style="cursor:pointer">Show HTML snippets</summary>

                <h4 style="margin:12px 0 6px">Background (HTML)</h4>
                <pre id="htmlBackground">&lt;ul&gt;
  &lt;li&gt;Unscheduled bleeding on HRT = bleeding on a regimen intended to be bleed-free (continuous combined), or bleeding outside the expected withdrawal bleed on sequential HRT.&lt;/li&gt;
  &lt;li&gt;A settling phase is common (up to 6 months after starting HRT or within 3 months of a regimen change).&lt;/li&gt;
  &lt;li&gt;Priorities: exclude non-uterine causes (cervix/vagina) and identify people needing urgent endometrial assessment.&lt;/li&gt;
&lt;/ul&gt;</pre>

                <h4 style="margin:12px 0 6px">Assessment (primary care) (HTML)</h4>
                <pre id="htmlAssessment">&lt;ul&gt;
  &lt;li&gt;&lt;strong&gt;Bleeding pattern:&lt;/strong&gt; timing relative to HRT start/change; heavy/prolonged/daily vs light/spotting; recurrence/persistence.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;HRT regimen details:&lt;/strong&gt; continuous combined vs sequential; exact products + doses; route (oral/transdermal); progestogen type/dose/days per month; adherence (missed progestogen).&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Risk factors:&lt;/strong&gt; BMI (major: ≥40; minor: 30–39), diabetes, PCOS; hereditary syndromes (Lynch/Cowden) if known.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Examination/tests:&lt;/strong&gt; abdominal + pelvic exam where appropriate; speculum if indicated; ensure cervical screening is up to date/eligible; consider swabs if discharge; document BMI.&lt;/li&gt;
&lt;/ul&gt;</pre>

                <h4 style="margin:12px 0 6px">Primary care management (HTML)</h4>
                <pre id="htmlPCM">&lt;ul&gt;
  &lt;li&gt;If &lt;strong&gt;low cancer-risk&lt;/strong&gt; and bleeding is within 6 months of starting HRT or within 3 months of a change: consider &lt;strong&gt;HRT/progestogen adjustments&lt;/strong&gt; for a total of up to 6 months (BMS), provided bleeding is not heavy/prolonged/daily.&lt;/li&gt;
  &lt;li&gt;Check adherence and whether a combined preparation would reduce missed progestogen.&lt;/li&gt;
  &lt;li&gt;Consider vaginal oestrogen if atrophic findings.&lt;/li&gt;
&lt;/ul&gt;</pre>

                <h4 style="margin:12px 0 6px">Who to refer (HTML)</h4>
                <pre id="htmlRefer">&lt;p&gt;&lt;strong&gt;Urgent assessment / imaging / gynae triage&lt;/strong&gt; is needed if bleeding is heavy/prolonged/daily, if major risk factors are present, or if bleeding persists despite appropriate regimen adjustments.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;If TVUS performed and endometrium is fully visualised and uniform (BMS):&lt;/strong&gt;&lt;/p&gt;
&lt;ul&gt;
  &lt;li&gt;&lt;strong&gt;ccHRT:&lt;/strong&gt; ET &lt;strong&gt;≤4 mm&lt;/strong&gt; → low risk; adjust HRT and review.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;sHRT:&lt;/strong&gt; ET &lt;strong&gt;≤7 mm&lt;/strong&gt; → low risk; adjust HRT and review.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;ccHRT:&lt;/strong&gt; ET &lt;strong&gt;&gt;4 mm&lt;/strong&gt; or &lt;strong&gt;sHRT:&lt;/strong&gt; ET &lt;strong&gt;&gt;7 mm&lt;/strong&gt; → refer on urgent pathway for endometrial assessment.&lt;/li&gt;
  &lt;li&gt;If endometrium is &lt;strong&gt;incompletely visualised&lt;/strong&gt; → treat as abnormal and refer per local pathway.&lt;/li&gt;
&lt;/ul&gt;

&lt;p class=&quot;small&quot;&gt;&lt;strong&gt;Referral letter: required information (triage metrics)&lt;/strong&gt;&lt;/p&gt;
&lt;ul&gt;
  &lt;li&gt;Bleeding pattern + timing relative to HRT start/change; heavy/prolonged/daily?&lt;/li&gt;
  &lt;li&gt;Exact HRT regimen (products, doses, route, start dates) + progestogen exposure (days/month) + adherence.&lt;/li&gt;
  &lt;li&gt;BMI and risk factors (diabetes, PCOS; Lynch/Cowden if known).&lt;/li&gt;
  &lt;li&gt;Exam findings incl speculum/cervix; cervical screening status.&lt;/li&gt;
  &lt;li&gt;If done: TVUS report (ET, uniformity, focal lesions/polyps, adnexal findings).&lt;/li&gt;
  &lt;li&gt;What adjustments have already been tried (and response).&lt;/li&gt;
&lt;/ul&gt;</pre>

                <h4 style="margin:12px 0 6px">Who not to refer (HTML)</h4>
                <pre id="htmlNotRefer">&lt;ul&gt;
  &lt;li&gt;Low-risk unscheduled bleeding within the expected settling phase may be managed with regimen optimisation and review (per BMS), provided bleeding is not heavy/prolonged/daily and there are no major risk factors.&lt;/li&gt;
&lt;/ul&gt;</pre>

                <h4 style="margin:12px 0 6px">References (HTML)</h4>
                <pre id="htmlRefs">&lt;ol&gt;
  &lt;li&gt;British Menopause Society (BMS) guideline: Management of unscheduled bleeding on HRT (Nov 2024). https://thebms.org.uk/wp-content/uploads/2024/12/01-BMS-GUIDELINE-Management-of-unscheduled-bleeding-HRT-NOVEMBER2024-A.pdf (retrieved 2026‑02‑09)&lt;/li&gt;
&lt;/ol&gt;</pre>
              </details>
            </div>

            <div id="draftText" class="section">
              <h3>Unscheduled bleeding on HRT</h3>

              <h4>Background</h4>
              <ul>
                <li>Unscheduled bleeding on HRT = bleeding on a regimen intended to be bleed-free (continuous combined), or bleeding outside the expected withdrawal bleed on sequential HRT.</li>
                <li>A settling phase is common (up to 6 months after starting HRT or within 3 months of a regimen change).</li>
                <li>Priorities: exclude non-uterine causes (cervix/vagina) and identify people needing urgent endometrial assessment.</li>
              </ul>

              <h4>Assessment (primary care) — collapsible</h4>
              <ul>
                <li><strong>Bleeding pattern:</strong> timing relative to HRT start/change; heavy/prolonged/daily vs light/spotting; recurrence/persistence.</li>
                <li><strong>HRT regimen details:</strong> continuous combined vs sequential; exact products + doses; route (oral/transdermal); progestogen type/dose/days per month; adherence (missed progestogen).</li>
                <li><strong>Risk factors:</strong> BMI (major: ≥40; minor: 30–39), diabetes, PCOS; hereditary syndromes (Lynch/Cowden) if known.</li>
                <li><strong>Examination/tests:</strong> abdominal + pelvic exam where appropriate; speculum if indicated; ensure cervical screening is up to date/eligible; consider swabs if discharge; document BMI.</li>
              </ul>

              <h4>Primary care management</h4>
              <ul>
                <li>If <strong>low cancer-risk</strong> and bleeding is within 6 months of starting HRT or within 3 months of a change: consider <strong>HRT/progestogen adjustments</strong> for a total of up to 6 months (BMS), provided bleeding is not heavy/prolonged/daily.</li>
                <li>Check adherence and whether a combined preparation would reduce missed progestogen.</li>
                <li>Consider vaginal oestrogen if atrophic findings.</li>
              </ul>

              <h4>Who to refer</h4>
              <p class="small">Include the triage metrics. Secondary care needs exact regimen + progestogen exposure + risk factors + TVUS details if available.</p>

              <ul>
                <li><strong>Urgent assessment / imaging / gynae triage</strong> if: heavy/prolonged/daily bleeding; major risk factors; persistent bleeding despite appropriate regimen adjustments; concerning exam findings.</li>
              </ul>

              <h4>TVUS thresholds (BMS 2024) — if endometrium uniform + fully visualised</h4>
              <ul>
                <li><strong>ccHRT:</strong> ET <strong>≤4 mm</strong> → low risk; adjust HRT and review.</li>
                <li><strong>sHRT:</strong> ET <strong>≤7 mm</strong> → low risk; adjust HRT and review.</li>
                <li><strong>ccHRT:</strong> ET <strong>&gt;4 mm</strong> or <strong>sHRT:</strong> ET <strong>&gt;7 mm</strong> → urgent pathway for endometrial assessment (biopsy and/or hysteroscopy).</li>
                <li>If endometrium <strong>incompletely visualised</strong> → treat as abnormal and refer per local pathway.</li>
              </ul>

              <h4>Referral letter: required information (triage metrics)</h4>
              <ul>
                <li>Bleeding pattern + timing relative to HRT start/change; heavy/prolonged/daily?</li>
                <li>Exact HRT regimen (products, doses, route, start dates) + progestogen exposure (days/month) + adherence.</li>
                <li>BMI and risk factors (diabetes, PCOS; Lynch/Cowden if known).</li>
                <li>Exam findings incl speculum/cervix; cervical screening status.</li>
                <li>If done: TVUS report (ET, uniformity, focal lesions/polyps, adnexal findings).</li>
                <li>What adjustments have already been tried (and response).</li>
              </ul>

              <h4>Who not to refer</h4>
              <ul>
                <li>Low-risk unscheduled bleeding within the expected settling phase may be managed with regimen optimisation and review (per BMS), provided bleeding is not heavy/prolonged/daily and there are no major risk factors.</li>
              </ul>

              <h4>Local agreement needed (drafting-site only)</h4>
              <ul>
                <li><label><input type="checkbox" disabled /> Confirm local access model: whether primary care can request TVUS directly for unscheduled bleeding on HRT, or if referral is required.</label></li>
                <li><label><input type="checkbox" disabled /> Confirm local referral destination wording (USOC/USCP vs urgent gynae) and how “abnormal scan” triggers triage.</label></li>
                <li><label><input type="checkbox" disabled /> Confirm whether D&amp;G uses any additional local thresholds beyond BMS (e.g., which regimens are adjusted first-line).</label></li>
              </ul>
            </div>
          </div>

          <div class="panel" role="tabpanel" data-panel="refs">
            <div class="section">
              <h3>References</h3>
              <ol>
                <li>British Menopause Society (BMS) guideline: Management of unscheduled bleeding on HRT (Nov 2024). <a href="https://thebms.org.uk/wp-content/uploads/2024/12/01-BMS-GUIDELINE-Management-of-unscheduled-bleeding-HRT-NOVEMBER2024-A.pdf">https://thebms.org.uk/wp-content/uploads/2024/12/01-BMS-GUIDELINE-Management-of-unscheduled-bleeding-HRT-NOVEMBER2024-A.pdf</a> (retrieved 2026‑02‑09)</li>
              </ol>
            </div>
          </div>

        </div>
      </div>
    </div>
  </div>

  <script src="../assets/site.js"></script>
</body>
</html>
